
Ventriculitis in neurocritical care patients presents high morbidity and mortality risks. This study evaluated piperacillin-tazobactam (PTZ) pharmacokinetics to optimize cerebrospinal fluid (CSF) drug exposure in critically ill neurosurgical patients. Despite substantial inter-individual variability and low CSF penetration of piperacillin (median 3.73%), effective dosing recommendations remain elusive. High plasma PTZ levels do not reliably translate to therapeutic CSF exposures, complicating treatment strategies for ventriculitis.
Like
Save
Share